Ipafricept
Also known as: Frizzled-8 Fc fusion protein, FZD8-Fc, FZD8‑Fc, Ipafricept, OMP-54F28, OMP‑54
Source Ipafricept at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ipafricept (OMP‑54) is a recombinant FZD8‑Fc fusion protein that sequesters Wnt ligands. It has been evaluated in early‑phase clinical trials for solid tumors such as pancreatic, colorectal, and ovarian cancer, but is not yet approved for any indication.
Mechanism of Action
Soluble decoy receptor consisting of the extracellular domain of Frizzled8 fused to an IgG1 Fc fragment; binds circulating Wnt ligands and prevents activation of Frizzled receptors, thereby inhibiting canonical Wnt/β‑catenin signaling in tumor cells.
Routes of Administration
Goals & Uses
- Ovarian cancer treatmentOncologyLow
- Pancreatic cancer treatmentOncologyLow
- Cancer stem cell targetingOncologyModerate
- Pancreatic cancerOncologyModerate
- Hepatocellular carcinoma treatmentOncologyLow
- Colorectal cancerOncologyModerate
Contraindications
- Active pregnancyReproductive SafetyHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe uncontrolled infectionInfectionModerate
Adverse Effects
- DysgeusiaNeurologicalUncommon
- Bone fracturesMusculoskeletalRare
- Infusion‑related reactionsGeneralCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- Muscle-related toxicity (myalgia, muscle weakness)MusculoskeletalCommon
- Decreased appetiteMetabolicCommonReduced desire to eat
- DiarrheaGastrointestinalUncommonLoose or frequent stools
- Bone density loss / skeletal effectsMusculoskeletalUncommon
Drug Interactions
- Cytotoxic chemotherapy agentsModerate
- Paclitaxel / CarboplatinModerate
- Nab-paclitaxel / GemcitabineModerate
- SorafenibModerate
Population Constraints
- Patients with pre-existing bone diseaseMusculoskeletalRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalClinical trial authorization granted for selected centers.
- United StatesInvestigationalIND in place for Phase I/II oncology trials.
- United KingdomInvestigationalUnder MHRA clinical trial approval.
Investigational biologic under clinical development; not approved by FDA, EMA, or MHRA. Used only within registered clinical trial protocols.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ipafricept?
Ipafricept (OMP‑54) is a recombinant FZD8‑Fc fusion protein that sequesters Wnt ligands. It has been evaluated in early‑phase clinical trials for solid tumors such as pancreatic, colorectal, and ovarian cancer, but is not yet approved for any indication.
What is Ipafricept used for?
Ipafricept is educationally associated with: Ovarian cancer treatment, Pancreatic cancer treatment, Cancer stem cell targeting, Pancreatic cancer, Hepatocellular carcinoma treatment, Colorectal cancer. Educational only — not medical advice.
How is Ipafricept administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Ipafricept?
Reported adverse effects include: Dysgeusia, Bone fractures, Infusion‑related reactions, Nausea, Fatigue, Muscle-related toxicity (myalgia, muscle weakness), Decreased appetite, Diarrhea, Bone density loss / skeletal effects. This list is not exhaustive — consult a qualified clinician.
Who should avoid Ipafricept?
Recorded contraindications: Active pregnancy, Severe hepatic impairment, Pregnancy, Severe uncontrolled infection. Consult a qualified clinician before use.